{"name":"Replimune Inc.","slug":"replimune-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":189447000,"netIncome":-247297000,"cash":111119000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxNY3A2YmU5QTE4OEpCUG1XdmFQT1lpUC1ieVgzX3hIWi1yWUFPVTBxWURCdFljZzRWWk0tbk45VnBoUHp2SWVyZXFzMVhrX3NKS2liTkNtb0llZnlxdkdrSHBzWUhncVZvTFkwcnlPbHU5R0MwTV9WMmdEWDB3QVlXcGJhTzZuVkNQa2xKb0J6dU1FXy1QU1VGSmhZaDlYbWdpVUlGWm0ybkhQbjVWaUk3T1JGLURzZ2xKckN4UFJzRTBfbG1tYTlWekN5NkJZQ2ZNLVBGbEl1N0lBMDVMM1hldVlwTVhZRjNnbWZXT21DbzlTZGJfczdDTGctajZHeUFibUJ6NlBqX2t4M0hBWWliNUZISnlObTRBeGZZSHo2UDBUY2NuWkRWTFBQVndvVkxhOEE?oc=5","date":"2026-04-07","type":"pipeline","source":"Barchart.com","summary":"Oncolytic Virus Therapies Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | CG Oncology, Imugene, Amgen, Daiichi Sankyo, Genelux, Replimune, Binhui Biopharma - Barchart.com","headline":"Oncolytic Virus Therapies Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | CG Oncology, Imugene, Amge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE53V0pxdXhsZmM4aU1OdlZoYTljclh6U29FZDZOcnZnakItSWNWVlNja3pWS2ctNFl0REQ4TmpGNVlTaGJIUkRUd0dRXzd0cl92YUVFWW9VSWpVMndoRm5nanpkVUZFOF9rS1M5M1NXM3NGUQ?oc=5","date":"2026-03-30","type":"regulatory","source":"BioSpace","summary":"6 FDA Decisions To Watch in Q2 2026 - BioSpace","headline":"6 FDA Decisions To Watch in Q2 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPUnhKTXQ4S2tzbk03c3pDUkdYbVRLMXBObGFSc3ZvQThVX2tUTVo2cDRJd29LUTVuS3FieVNnRnVLakxGUDNPT25tUnFKMWRjU21Ecjh1UXAwSFYtVTdjelVPcDN4bXk5WjdwdkpDOVN6eU9IcGItNTRpMTZWRnZPREpHYlRYRTFZYklBclR4SWtTSHJfTlFseElYLTlna0FwSnBSeVpCbUNMeU41MFBrdTQ0aUt5eFlvNmlyeVI1Q2UyUQ?oc=5","date":"2026-03-04","type":"deal","source":"TradingView","summary":"ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - TradingView","headline":"ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M","sentiment":"neutral"},{"date":"2026-02-03","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQU0RVT2pEak5aZnVRM3Z5UWZaTEIzSXVFX1JEa29rMkRMdl9EN0Y4Ukk4MlM5cWdzaG5qUWJHa1lEQXo3SmFiYlVvbDRNRE9MZmdwWHVVd3VhQ2tZYVpBQzZUeVBHcWk4bC1wY2FXdmY0cGhJNklkX0tVLVBVTWVmMV9vUVd3bURMSzY4SVNISDZBMmQ5?oc=5","date":"2025-12-31","type":"pipeline","source":"Finviz","summary":"Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - Finviz","headline":"Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOaHhjVUE3VjFMWVloMUFGNGVZalRrbFpNbUN4S0tzN2ExUnFnQ3B4SUJRc3haLW1pZExWMXJZLVZLa2hodFdvbzYwNmdmaHRDbzVPNzZYVVlCR1N0SXdla2s3V1lhRk1zS25zeV8ySXFFUXNCU0VTTklWYlhNTlFQdGNrbHg1ekx3MWFHTElRUHVjRUFqcDhCN3ZzZElYeFZsUlVhQ2JjNU40UQ?oc=5","date":"2025-09-18","type":"regulatory","source":"The Business Journals","summary":"Melanoma drug developer stock crashes after report from FDA meeting - The Business Journals","headline":"Melanoma drug developer stock crashes after report from FDA meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNTkF4SjBPS01MdURwbjNoanNMQWJTczdSY3BvU2NkS1p6S1FpUEw0eUpJdE16RnBfOHg4OEJjdmoxQVhiZFpRRUJqRjhXajBlRWtnY3ZsT0E2UUhySHNVbmRIMmN1T3dqQ2I4c1Q4bFJEUUtPS05xTHBlazRwZ01rdkhrc2dOVUpaUXpQcTFLU0RMdXF6dHhVT2daai1BQQ?oc=5","date":"2025-07-25","type":"regulatory","source":"Pharmaceutical Executive","summary":"Replimune CRL Fallout: How Biopharma Leaders Should Manage a New Layer of FDA Uncertainty - Pharmaceutical Executive","headline":"Replimune CRL Fallout: How Biopharma Leaders Should Manage a New Layer of FDA Uncertainty","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOUXdMZFloSjFjNDA2VEJKNGlBeG42ekJVbkZGbnNkcGFvSWdrT0tCSlNsM3A4dm5HTjJwekdBRnR6ZjVkYkVfb3lyd1NzVjRlajRKS256T2FJdkdPcHpzN3VIWjVnTXh3dGdYbk5PdnA5LTBXV0d6NHBwelZQQlhaQ1QxcUQ?oc=5","date":"2025-07-23","type":"pipeline","source":"pharmaphorum","summary":"Replimune receives CRL on BLA for RP1 for advanced melanoma - pharmaphorum","headline":"Replimune receives CRL on BLA for RP1 for advanced melanoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQR25oaHVyT19xNko2UXdzMTR6d1M3dXl6ZDlpNnlpUDR3RU9obnZ1NkRpTkxwLTd3YTloMTZrcXdmT1docmtNQjh5di0xaHBpUzBwc2twcHRqRGZzdzAyTTViZVBNdGtCNjE3Z3hVTENRZ0h6aW9Ody1QZ1hNN3RveW54Ny03UjE2MzdQcVVDRGotUDl1azVlYnNKTTktTUZXU3BiRl94VXJHeXRBS1BIM19vUjF5S21xeFdrOUlWSnVWMG5MZ1VKTg?oc=5","date":"2025-07-22","type":"regulatory","source":"Pharmacy Times","summary":"FDA Issues CRL to Replimune for Vusolimogene Oderparepvec With Nivolumab for Advanced Melanoma - Pharmacy Times","headline":"FDA Issues CRL to Replimune for Vusolimogene Oderparepvec With Nivolumab for Advanced Melanoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBKZTFXbGl3Y2RBWHVQYUpCc0FONW1pSTFLSUJJS1ZjLThLV0hHcmF2V3Nza01zTFpFdFl4TDRUSm5oTXVVLWg3alRubDdZN0FGVjlNSTV1MWNmUTdMcTA3Qm4tTjRRUGVhb0d0T2ppeUY5UVIzaFdodnJpWm1hUQ?oc=5","date":"2025-07-22","type":"regulatory","source":"Barron's","summary":"Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment - Barron's","headline":"Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment - Barron's","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE55WFZDakgwQUZxbEVWN29JN3FBYkNNeFNxV043UGctcmxCTnhoY2hZOEtaTzJ6YUFxTUhsU2dpdVdFYmJjQ0t3WVkyRXFHdDV3U0FfTDdxSzJCSEFBRERpZnktQ1BoRG8xcmI1blloZDk2UTFIVTAtNmxn?oc=5","date":"2025-07-14","type":"regulatory","source":"BioSpace","summary":"FDA Action Alert: Roche, GSK, Regeneron, More - BioSpace","headline":"FDA Action Alert: Roche, GSK, Regeneron, More","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxPSlFhcVdwaFlONm5LenM3akJpY2hmc04zT3hMeWFVMm50ZTBMTWNZNlFWRFBUOUdJZ010blhQNkpKR1gzd2NwN0lDOXFRQlFQVmZZSW82aDRiYU94a3VaZDkxWWsxTWJGUEJlNnJWa1pGV2FEZkFLX3QyVWJJSDQ2ajgxZnVQY25wZnloZ3RBOVR4RGhSZ1REYjhHWGhzeTlmVjFmbEQ5b1ZSTktKQzltVDM0bHdBNm1DSEM2S1VSbEl0a0QybjUzZE5laFF2YTFqSkZNYlVrdXBKQm9lVjlZTTZiSDMwa3YzMUgwaHAxeV82LVNKZTFoZUI5ZG1NbThqUlE5bEFBUWJ6Rm5XcVV5Q2VWNl9NREdCN2lycUhOU2otUEh6NDBmSERtS3VPaENoMnI3M0tKRmxmTjg?oc=5","date":"2025-05-13","type":"trial","source":"GlobeNewswire","summary":"Metastatic Colorectal Cancer Clinical Trial Pipeline - GlobeNewswire","headline":"Metastatic Colorectal Cancer Clinical Trial Pipeline","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNNS1TTDdWYXdlM1B3THZNc2MtX1V6NUd0aURnSFdyam1RZDhROV9aMU1OV0FIdVY4X1NOU0k2VXdpMDNPa09OMVRhUGJpRWRIdzJ5N1ZDZ1d6aHMzbXItQ3hhYmhSWWw4NGNrNzJjZVJPdnFjQzljZW5CQ01sOWtYQkZ3RVVJTXQ4U0tkOFhOSlZsdEl5NzNlZlFpQ0RTOFhNVWV5SktJRDQ3bHcyQ3RILXludw?oc=5","date":"2025-04-28","type":"pipeline","source":"Seeking Alpha","summary":"Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma (NASDAQ:REPL) - Seeking Alpha","headline":"Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma (NASDAQ:REPL)","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":189447000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-247297000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":111119000,"cashHistory":[],"totalAssets":551328000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}